This interview with a Germany-based key opinion leader provides insights into current prescribing habits for sickle cell disease, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for sickle cell disease. Key assets highlighted include Endari, Adakveo, Oxbryta, Pyrukynd, etavopivat, inclacumab, osivelotor, Casgevy and Lyfgenia. 

This interview was conducted on 05 September 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.